Insider Purchases: Inside the Buy
Tag: contrarian investing
Coursera Stock (COUR): An $11.4 Million Activist Bet on a Turnaround
Pale Fire Capital just invested another $11.4 million in Coursera. With the stock down roughly 92% from its peak, institutions holding nearly 96% of the float, $85 million-plus in targeted Udemy synergies and a $500 million buyback, COUR may be an asymmetric turnaround—or a remarkably well-funded value trap.
🤖 Upstart (UPST): $7.65M Founder Buying Meets a 30.6% Short-Squeeze Fuse 💳⚡
Upstart CEO Paul Gu and Executive Chairman Dave Girouard have bought roughly $7.65 million of UPST stock. Now revenue is growing 42%, GAAP profitability has returned—and 30.6% of the float is short. We dissect one of fintech’s most fascinating battleground stocks.
🩺 Alphatec (ATEC): CEO’s $1M Buy, Positive Free Cash Flow & an 11% Short-Squeeze Fuse 🦾🦴
Alphatec CEO Pat Miles just put $1.01 million of his own money into ATEC at $8.81. With positive free cash flow, improving EBITDA, Valence robotics and 11% short interest, is this battered spine-medtech stock finally reaching its turnaround moment?
🦴 Enovis (ENOV): CEO Buys the $19 Crash—Is This Falling Knife Finally a Buy? 🤖
Enovis CEO Damien McDonald bought ENOV again after shares collapsed toward $19. Insiders are accumulating, institutions remain heavily invested, analysts see substantial upside and adjusted valuation has fallen below 5x forward earnings. But short interest is high, leverage and integration risks remain—and momentum is dreadful. ENOV may be the ultimate FunStock signal collision.
💳 Klarna (KLAR): A $10M CEO Buy, 42% TMD Growth & a 75% Post-IPO Crash
Klarna has fallen roughly 75% from its post-IPO high, yet revenue rose 27%, transaction margin dollars surged 42%, and co-founder/CEO Sebastian Siemiatkowski just bought $9.95 million of KLAR. Is Wall Street pricing a broken fintech—or overlooking a rapidly evolving payments platform?
🐾 Zoetis (ZTS): A Premium Veterinary Titan Sitting in the Doghouse
Zoetis (ZTS) may be one of the most interesting “quality in the doghouse” setups of 2026. The global animal-health leader is still profitable, institutionally loved, and backed by powerful pet-humanization trends — yet soft U.S. pet spending, competition, and lowered guidance have crushed the stock. With directors buying near the lows and forward P/E near 11x, is ZTS finally becoming a value play?
💳 PayPal (PYPL): An 8× P/E, a CFO Insider Buy, and Why This FinTech Giant May Be Too Cheap to Ignore
PayPal has lost more than 85% of its value since 2021, yet it continues to grow revenue, generate billions in free cash flow, and aggressively repurchase shares. Has Wall Street become too pessimistic, or is PYPL a classic value trap? We examine the bull case, the risks, and what could reignite growth.
🏝️ The 125% Float Monopoly: Inside Oxford Industries' High-Conviction Floor and the 8-Day Island Squeeze
With insiders buying, institutions owning more than the float itself, a 7.5% dividend yield and Tommy Bahama still thriving, Oxford Industries presents one of the more unusual setups in retail.
🍩 Krispy Kreme (DNUT): The 3G Mastermind, 7-Day Squeeze Trap, and the Great Post-IPO Cash Flow Resuscitation
Krispy Kreme shares remain down more than 80% from their highs, but insiders—including former 3G Capital executive Bernardo Hees—are buying aggressively. With free cash flow finally turning positive and margins improving, the iconic doughnut maker may be entering a new chapter.
🥚 Vital Farms (VITL): The Great Egg Glut of 2026
Vital Farms stock has been absolutely scrambled by the 2026 egg glut, plunging more than 80% from its highs as profitability collapsed and short sellers flooded the farm. But coordinated insider buying, a debt-free balance sheet, and extreme institutional ownership suggest the setup may be far more explosive than the market currently realizes.